ReviewDrugs2026
Biased Kappa-opioid Agonist Strategies in Pain Management: Approaches to Clinical Benefits with Reduced Adverse Effects.
Review in Drugs, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Optimizing transversus abdominis plane blocks in colorectal surgery: methodological queries and the fundamental question of indication.Langenbeck's archives of surgery · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mu-opioid receptor (MOR) agonists remain the cornerstone of pain management but are limited by respiratory depression, tolerance, dependence, and mood disturbances. Kappa-opioid receptor (KOR) agonists offer complementary analgesic mechanisms with minimal abuse potential, yet clinical utility is restricted by dysphoria, sedation, and anxiety. This review critically evaluates emerging strategies that leverage both receptor systems through G-protein-biased KOR agonists and bifunctional KOR/MOR ligands. While preclinical evidence suggests that these approaches may provide additive analgesia with reduced adverse effects, significant challenges remain in translating these findings to clinical practice. The controversy surrounding G-protein bias measurement and the limited clinical data available highlight the need for cautious optimism regarding these novel therapeutic approaches.
Indexed as
Identifiers
41498917What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.